How to Increase Toujeo Dose from 40 Units
Increase Toujeo by 2 units every 3 days until fasting plasma glucose reaches 100–120 mg/dL (5.5–6.7 mmol/L), monitoring daily to avoid hypoglycemia. 1
Standard Titration Protocol
The FDA-approved labeling for Toujeo specifies that dose titration should occur no more frequently than every 3 to 4 days based on metabolic needs, blood glucose monitoring results, and glycemic control goals. 2
Specific titration increments:
- Increase by 2 units every 3 days as the standard approach for basal insulin glargine titration 1
- Alternative patient-managed titration: increase by 2 units every 3 days in the absence of blood glucose <70 mg/dL 3
- More aggressive clinic-managed approach: adjust by 0–2,4, or 6–8 units based on mean fasting plasma glucose over the previous 3 days (if FPG is ≥100–<120, ≥120–<140, ≥140–<180, or ≥180 mg/dL, respectively) 3
Target Glucose Goals
Aim for fasting plasma glucose of 100–120 mg/dL (5.5–6.7 mmol/L) as the primary titration target. 1 The FDA labeling recommends individualizing targets, with a general goal of 80–130 mg/dL for most patients. 2
Maximum Dose Considerations
- Do not exceed 0.5–1.0 units/kg/day of basal insulin without achieving target; if glucose remains elevated despite reaching this threshold, consider adding a GLP-1 receptor agonist instead of further basal insulin escalation 1
- At 40 units daily (approximately 0.4 units/kg for an average adult), you are not yet at the overbasalization threshold 1
- Real-world data shows Toujeo was successfully uptitrated to a mean dose of 40 units per day with good glycemic control 4
Safety Monitoring During Titration
Check fasting blood glucose daily during active dose titration. 1, 2 The FDA mandates increased frequency of blood glucose monitoring during any changes to insulin regimens. 2
If any glucose reading is <70 mg/dL:
- Reduce the basal dose by 10–20% immediately (e.g., from 40 U to 32–36 U) 1, 5
- This dose reduction is mandatory even if the cause of hypoglycemia is not yet identified 5
Important Toujeo-Specific Considerations
Toujeo requires higher daily doses than Lantus (insulin glargine 100 U/mL) to maintain equivalent glycemic control due to its concentrated formulation and different pharmacokinetic profile. 2, 6 The maximum glucose-lowering effect of a Toujeo dose may take five days to fully manifest, so patience is required during titration. 2
Pen selection matters at this dose:
- At 40 units, you can use either the TOUJEO SoloStar (delivers 1-unit increments, up to 80 units per injection) or the TOUJEO Max SoloStar (delivers 2-unit increments, up to 160 units per injection, recommended for doses ≥20 units/day) 2
- If switching between pens and your dose is an odd number, adjust by 1 unit to match the pen's increment capability 2
When to Reassess the Approach
If fasting glucose remains above target for ≥3 days after a dose increase, continue titrating upward rather than waiting weeks (avoid therapeutic inertia). 1 However, if you reach approximately 0.5 units/kg/day without achieving fasting glucose goals, reassess the overall strategy:
- An elevated bedtime-to-morning glucose differential with adequate fasting glucose suggests you may need prandial insulin coverage rather than more basal insulin 1
- Consider adding a GLP-1 receptor agonist before further basal insulin escalation 1
- Post-prandial glucose control becomes critical for achieving HbA1c <7% once basal insulin is optimized 7